Renal cell carcinoma: a critical analysis of metabolomic biomarkers emerging from current model systems

• Type: Another Publication in an International Scientific Journal
• Date: 2017

Authors

Rodrigues D (Author) Other; Monteiro M (Author) Other; Carmen Jeronimo (Author) ICBAS; henrique, rmf (Author) ICBAS; Belo, L (Author) FFUP; Maria de Lourdes Bastos (Author) FFUP; Paula Guedes de Pinho (Author) FFUP; Carvalho M (Author) Other

Journal

Title: Translational Research

Vol. 180

Pages: 1-11

ISSN: 1931-5244

Publisher: Elsevier

Indexing

ISI Web of Knowledge - 26 Citations

Scopus - 24 Citations

Other information

Authenticus ID: P-00M-G6E

DOI: 10.1016/j.trsl.2016.07.018

Abstract (EN): Metabolomics, an emerging field of "omics" sciences, has caught wide scientific attention in the area of biomarker research for cancers in which early diagnostic biomarkers have the potential to greatly improve patient outcome, such as renal cell carcinoma (RCC). Metabolomic approaches have been successfully applied to various human RCC model systems, mostly ex vivo neoplastic renal tissues and biofluids (urine and serum) from patients with RCC. Importantly, in contrast to other cancers, only a few studies have addressed the RCC metabolome using cancer cell culture-based in vitro models. Herein, we first carried out a comprehensive review of current metabolomic data in RCC, with emphasis on metabolite disturbances and dysregulated metabolic pathways identified in each of these experimental models. We then critically analyzed the consistency of evidence in this field and whether metabolites found altered in tumor cell and tissue microenvironment are reflected in biofluids, which constitute the rationale underlying the translation of discovered metabolic biomarkers into noninvasive diagnostic tools. Finally, dominant metabolic pathways and promising metabolites as biomarkers for diagnosis and prognosis of RCC are outlined.

Language: English

Type (Professor's evaluation): Scientific

No. of pages: 11